cadazolid

{{Short description|Chemical compound}}

{{Drugbox

| drug_name =

| IUPAC_name = 1-Cyclopropyl-6-fluoro-7-[4-({2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenoxy}methyl)-4-hydroxypiperidin-1-yl]-4-oxo-1,4-dihydroquinolin-3-carboxylic acid

| image = Cadazolid.svg

| alt =

| caption =

| width = 250

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status = Investigational

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number = 1025097-10-2

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 2OEA2UN10Y

| KEGG = D11207

| ATCvet =

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank =

| ChemSpiderID = 30774277

| C=29 | H=29 | F=2 | N=3 | O=8

| smiles = OC(C1=CN(C2CC2)C3=C(C=C(F)C(N4CCC(COC5=C(F)C=C(N6C[C@H](CO)OC6=O)C=C5)(O)CC4)=C3)C1=O)=O

| StdInChI = 1S/C29H29F2N3O8/c30-21-10-19-23(33(16-1-2-16)13-20(26(19)36)27(37)38)11-24(21)32-7-5-29(40,6-8-32)15-41-25-4-3-17(9-22(25)31)34-12-18(14-35)42-28(34)39/h3-4,9-11,13,16,18,35,40H,1-2,5-8,12,14-15H2,(H,37,38)/t18-/m1/s1

| StdInChIKey = XWFCFMXQTBGXQW-GOSISDBHSA-N

}}

Cadazolid is an experimental antibiotic of the oxazolidinone class made by Actelion Pharmaceuticals Ltd. which is effective against Clostridioides difficile, a major cause of drug resistant diarrhea in the elderly.{{cite web |url=http://www.internalmedicinenews.com/index.php?id=2049&type=98&tx_ttnews%5Btt_news%5D=137097&cHash=da03e20e36 |title=Promising C. difficile Antibiotic in Pipeline |last1=Boschert |first1=Sherry | name-list-style = vanc |date=19 September 2012 |website=Internal Medicine News |publisher= International Medical News Group |access-date=22 May 2013}} Current drug treatments for this infection involve orally delivered antibiotics, principally fidaxomicin, metronidazole and vancomycin; the last two drugs are the principal therapeutic agents in use, but fail in approximately 20 to 45% of the cases. The drug works by inhibiting the synthesis of proteins in the bacteria, thus inhibiting the production of toxins and the formation of spores.{{cite web |url=http://www1.actelion.com/en/scientists/development-pipeline/phase-2/cadazolid.page |title=Cadazolid |publisher=.actelion.com |access-date=2013-05-22 |archive-url=https://web.archive.org/web/20130609070712/http://www1.actelion.com/en/scientists/development-pipeline/phase-2/cadazolid.page |archive-date=2013-06-09 |url-status=dead }} Cadazolid progressed through to Phase III clinical trials, but in its financial results for Q1 2018, Idorsia mentions that Actelion informed them that "following completion of Phase 3 data analysis of cadazolid - it has decided to discontinue the development of the compound."{{Cite web|url=https://www.idorsia.com/media/news-details?newsId=2185240|title=Idorsia announces financial results for the first quarter 2018|date=April 19, 2018|website=Idorsia|access-date=April 27, 2018|archive-url=https://web.archive.org/web/20180428011732/https://www.idorsia.com/media/news-details?newsId=2185240|archive-date=April 28, 2018|url-status=dead}}

__TOC__